The U.S. Drug Enforcement Agency is recommending that cannabis be reclassified as a Schedule III drug‚ which would codify that it has medicinal value and is less dangerous than its current Schedule I designation‚ Axios has confirmed. Why it matters: The U.S. cannabis industry needed a win‚ just days after one of its best-known companies‚ MedMen‚ filed for bankruptcy protection. Venture capital investment in cannabis companies has fallen sharply in the past couple of years‚...